Aggressive lowering of blood pressure

Lancet

Volumn 368, Issue 9536, 2006, Pages 627-628

  Kannel, William B ^a   Vasan, Ramachandran S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNSPECIFIED SIDE EFFECT;

EID: 33747198805     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69224-6     Document Type: Note

References (15)

1. Chobanian A., Bakris G., Black H., and The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure. Hypertension 42 (2003) 1206-1252
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
3. Guidelines Sub-Committee. 1999 World Health Organization-International Society for Hypertension guidelines for the treatment of hypertension. J Hypertens 17 (1999) 151-183
4. Perry Jr. H., McDonald R., Hulley S., et al. Systolic hypertension in the elderly program, pilot study (SHEP-PS): morbidity and mortality experience. J Hypertens Suppl 6 (1986) S21-S23
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265 (1991) 3255-3264
6. Staessen J., Fagard R., Thijs L., and for the The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350 (1997) 757-764
7. Wang J., Staessen J., Gong L., and Liu L. Chinese trial on isolated hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 160 (2000) 211-220
8. Cruickshank J., Thorp J., and Zacharias F. Benefits and potential harm of lowering high blood pressure. Lancet 1 (1987) 581-584
9. Messerli F., Mancia G., Conti R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006) 884-893
10. D'Agostino R., Belanger A., Kannel W., and Cruickshank J. Relation of low blood pressure to coronary heart disease death in presence of myocardial infarction. The Framingham Study. BMJ 303 (1991) 385-389
11. Kannel W., Sorlie P., Castelli W., and McGee D. Blood pressure and survival after myocardial infarction. Am J Cardiol 45 (1980) 326-330
12. Kannel W., Wilson P., Nam B., D'Agostino R., and Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 94 (2004) 380-384
13. Messerli F., Franklin S., Mancia G., Hewkin A., Kupfer S., and Pepine C. Increased pulse pressure is strongly associated with adverse cardiovascular outcomes. The International Verapamil SR-Trandolapril Study (INVEST) abstract 2006 (2004). http://www.abstractsonline.com/arch/RecordView.aspx?LookupKey=12345& recordID=2384 (accessed Aug 10, 2006)
14. Hansson L., Zanchetti A., Carruthers S., and for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 351 (1998) 1755-1762
15. Wang J., Staessen J., Franklin S., Fagard R., and Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 45 (2005) 907-913